American Well (NYSE:AMWL – Get Free Report) and Aclarion (NASDAQ:ACON – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, dividends, institutional ownership, risk, earnings, profitability and analyst recommendations.
Institutional & Insider Ownership
56.0% of American Well shares are owned by institutional investors. Comparatively, 7.5% of Aclarion shares are owned by institutional investors. 12.8% of American Well shares are owned by insiders. Comparatively, 0.0% of Aclarion shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Earnings and Valuation
This table compares American Well and Aclarion”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| American Well | $249.32 million | 0.79 | -$95.70 million | ($4.77) | -2.49 |
| Aclarion | $83,769.00 | 64.37 | -$7.23 million | ($7.40) | -0.25 |
Aclarion has lower revenue, but higher earnings than American Well. American Well is trading at a lower price-to-earnings ratio than Aclarion, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
American Well has a beta of 1.67, meaning that its stock price is 67% more volatile than the S&P 500. Comparatively, Aclarion has a beta of 1.2, meaning that its stock price is 20% more volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of current recommendations for American Well and Aclarion, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| American Well | 1 | 5 | 1 | 0 | 2.00 |
| Aclarion | 1 | 0 | 1 | 0 | 2.00 |
American Well currently has a consensus price target of $9.50, suggesting a potential downside of 19.90%. Aclarion has a consensus price target of $7.50, suggesting a potential upside of 300.86%. Given Aclarion’s higher probable upside, analysts plainly believe Aclarion is more favorable than American Well.
Profitability
This table compares American Well and Aclarion’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| American Well | -35.75% | -30.12% | -22.30% |
| Aclarion | -10,948.81% | -59.34% | -56.12% |
Summary
American Well beats Aclarion on 8 of the 12 factors compared between the two stocks.
About American Well
American Well Corporation, an enterprise platform and software company, delivers digitally enabling hybrid care in the United States and internationally. The company offers Converge, a cloud-based platform that enables health providers, payers, and innovators to provide in-person, virtual and automated care; and delivers virtual primary care, post-discharge follow-up, chronic condition management, virtual nursing, e-sitting, on-demand and scheduled virtual visits, specialty consults, automated care, and behavioral health, as well as specialty care programs, including dermatology, musculoskeletal care, second opinion, and cardiometabolic care to patients and members. It provides Carepoint devices comprising carts, peripherals, tablets, and TVs, which serve as digital access points in clinical settings. In addition, the company offers Amwell Medical Group network services consisting of primary and urgent care, behavioral health therapy, acute psychiatry, lactation counseling, and nutrition services. Further, it provides professional services to facilitate implementation, workflow design, systems integration, and service expansion for its products, as well as patient and provider engagement services. The company sells its products through field sales professionals, channel partners, and value-added resellers. American Well Corporation was incorporated in 2006 and is headquartered in Boston, Massachusetts.
About Aclarion
Aclarion, Inc., a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.
Receive News & Ratings for American Well Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for American Well and related companies with MarketBeat.com's FREE daily email newsletter.
